Robin Wijsman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Robin Wijsman has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Fred J.F. Ubbels
Department of Radiation Oncology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
2 shared publications - Johannes Albertus Langendijk
Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
2 shared publications - Abraham Rutgers
Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
1 shared publication - Alessia De Biase
University Medical Center Groningen (UMCG)
1 shared publication - Anke van Den Berg
Department of Pathology & Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
1 shared publication - Anne G. H. Niezink
Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 22 February 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 52, 100935
Recovery of quality of life in 574 patients with inoperable lung cancer undergoing (chemo)radiotherapy
- 22 February 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 52, 100935
Open AccessRecovery of quality of life in 574 patients with inoperable lung cancer undergoing (chemo)radiotherapy
- Open Access
- 26 July 2024
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 31, 100616
A planning study of proton therapy dose escalation for non-small cell lung cancer
- 26 July 2024
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 31, 100616
Open AccessA planning study of proton therapy dose escalation for non-small cell lung cancer
- Open Access
Baseline Blood CD8+ T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer
Background: Tumor-infiltrating immune cells have been correlated with prognosis for patients treated with immune checkpoint inhibitor (ICI) treatment of various cancers. However, no robust biomarker has been described to predict treatment response yet. We hypothesized that the activation potency of circulating T cells may predict response to ICI treatment. Methods: An exploratory analysis was conducted to investigate the association between the response to immune checkpoint inhibition (ICI) combined with stereotactic radiotherapy (SBRT) and the potency of circulating T cells to be activated. Blood-derived lymphocytes from 14 patients were stimulated ex vivo with, among others, Staphylococcal enterotoxin B (SEB) and compared to healthy controls (HCs). Patients were grouped into responders (>median progression free survival (PFS)) and non-responders (+ and CD8+ T cells in response to stimulation was measured using flow cytometry. In addition, serum levels of BAFF, IFNγ, and IL-2 receptor (sIL-2R) were measured by Luminex. Results: At baseline, a higher percentage of activated CD8+ T cells (15.8% vs. 3.5% (p = +CD69+CD8+ T cells (8.8% vs. 2.9% (p = 0.02)) was observed in responders compared to non-responders upon ex vivo stimulation with SEB. The concurrently measured serum cytokine levels were not different between responders and non-responders. Conclusion: Baseline blood CD8+ T cell activation potency, measured by intracellular cytokine production after ex vivo stimulation, is a potential biomarker to discriminate responders from non-responders to SBRT combined with ICI.
Open AccessBaseline Blood CD8+ T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer
Background: Tumor-infiltrating immune cells have been correlated with prognosis for patients treated with immune checkpoint inhibitor (ICI) treatment of various cancers. However, no robust biomarker has been described to predict treatment response yet. We hypothesized that the activation potency of circulating T cells may predict response to ICI treatment. Methods: An exploratory analysis was conducted to investigate the association between the response to immune checkpoint inhibition (ICI) combined with stereotactic radiotherapy (SBRT) and the potency of circulating T cells to be activated. Blood-derived lymphocytes from 14 patients were stimulated ex vivo with, among others, Staphylococcal enterotoxin B (SEB) and compared to healthy controls (HCs). Patients were grouped into responders (>median progression free survival (PFS)) and non-responders (+ and CD8+ T cells in response to stimulation was measured using flow cytometry. In addition, serum levels of BAFF, IFNγ, and IL-2 receptor (sIL-2R) were measured by Luminex. Results: At baseline, a higher percentage of activated CD8+ T cells (15.8% vs. 3.5% (p = +CD69+CD8+ T cells (8.8% vs. 2.9% (p = 0.02)) was observed in responders compared to non-responders upon ex vivo stimulation with SEB. The concurrently measured serum cytokine levels were not different between responders and non-responders. Conclusion: Baseline blood CD8+ T cell activation potency, measured by intracellular cytokine production after ex vivo stimulation, is a potential biomarker to discriminate responders from non-responders to SBRT combined with ICI.
- 29 August 2023
- Published by Morressier GmbH
Automatic Early Stage Tumor Delineation on the 10 Breathing Phases of 4DCT
**Abstract text** Stereotactic body radiotherapy (SBRT) is the standard approach for patients with early stage lung cancer who are inoperable bec | POSTER
- 29 August 2023
- Published by Morressier GmbH
Automatic Early Stage Tumor Delineation on the 10 Breathing Phases of 4DCT
**Abstract text** Stereotactic body radiotherapy (SBRT) is the standard approach for patients with early stage lung cancer who are inoperable bec | POSTER